Demidowich AP, et al. - In people with obesity and metabolic syndrome (MetS), researchers assessed the effectiveness and safety of colchicine for improving metabolic and inflammatory outcomes. For three months, adults with obesity and MetS but without diabetes were randomized to colchicine 0.6mg or placebo capsules twice daily. According to this pilot study, colchicine significantly improved inflammatory variables associated with obesity and showed a good safety profile among diabetes-free adults with obesity and MetS. These findings suggest that a larger, properly powered study should be conducted to determine whether colchicine improves insulin resistance and other metabolic health measures in at-risk people.